Get started
Author

Nicola Fenwick

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial
2022 · Bernadette Brennan, Laura Kirton, et al. · The Lancet · 159
PDF
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol
2020 · Jennifer Anderton, Veronica Moroz, et al. · Trials · 129
PDF
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
2013 · Helena M Earl, Anne-Laure Vallier, et al. · The Lancet Oncology · 121
PDF
Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
2022 · Martin McCabe, Laura Kirton, et al. · Journal of Clinical Oncology · 47
Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
2020 · Martin G. McCabe, Laura Kirton, et al. · Journal of Clinical Oncology · 45
Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.
2019 · Martin G. McCabe, Veronica Moroz, et al. · Journal of Clinical Oncology · 44
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
2013 · E Provenzano, A-L Vallier, et al. · British Journal of Cancer · 33
PDF
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
2024 · Lucas Moreno, Rebekah Weston, et al. · Journal of Clinical Oncology · 30
Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR)
2009 · H. M. Earl, A. Vallier, et al. · Journal of Clinical Oncology · 28
RETRACTED: PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults
2024 · Nicola Fenwick, Rebekah Weston, et al. · Frontiers in Oncology · 17
Sentinel lymph node biopsy (SLNB) prior to primary chemotherapy (PC) in breast cancer patients.
2009 · GC Wishart, JR Benson, et al. · Cancer Research · 2
Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial.
2020 · Keith Wheatley, Bryar Kadir, et al. · Journal of Clinical Oncology · 1
Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design
2013 · Josephine Khan, Christina Yap, et al. · Trials · 1
PDF
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
2024 · Lucas Moreno, Rebekah Weston, et al. · Newcastle University ePrints (Newcastle Univesity)
O-110 The challenges of using radiological ‘tumour response’ as an endpoint in Neo-tAnGo: a national neo-adjuvant chemotherapy breast cancer trial
2007 · L. Hiller, N. Fenwick, et al. · European Journal of Cancer Supplements
Works count: 18
Citation count: 657
H-index: 10
I10-index: 10
Year
Topic
Type